Drug:
Reaction: ACCIDENTAL EXPOSURE TO PRODUCT
20250101 - 20251231
No. 601 - 700
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 601 | 25055986 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 602 | 25055996 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 603 | 25056182 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 604 | 25057968 |
29 | 2 | |
Accidental exposure to product, Hair texture abnormal, Alopecia, Tinnitus, Skin burning sensation, |
||||
NAPROXEN SODIUM, NAPROXEN SODIUM TABLET, |
||||
| 605 | 25054556 |
US |
47 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 606 | 25054568 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 607 | 25054572 |
US |
43 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 608 | 25054574 |
US |
45 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 609 | 25054602 |
US |
||
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 610 | 25054611 |
US |
65 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 611 | 25054615 |
US |
||
Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 612 | 25054628 |
US |
61 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 613 | 25054712 |
US |
9 | 2 |
Injection site pruritus, Exposure via skin contact, Accidental exposure to product, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 614 | 25054959 |
US |
66 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 615 | 25055036 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 616 | 25055050 |
US |
3 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 617 | 25055198 |
US |
70 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 618 | 25055341 |
US |
5 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 619 | 25055387 |
US |
74 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 620 | 25055552 |
US |
22 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 621 | 25048222 |
US |
||
Accidental exposure to product, Device leakage, Drug dose omission by device, Exposure via skin contact, |
||||
GUSELKUMAB, |
||||
| 622 | 25048371 |
US |
1 | |
Accidental exposure to product, Device malfunction, Device issue, Drug dose omission by device, |
||||
SECUKINUMAB, AMLODIPINE, TIRZEPATIDE, |
||||
| 623 | 25048389 |
US |
83 | 1 |
Injury associated with device, Accidental exposure to product, Incorrect dose administered by device, Device difficult to use, Device use error, Drug dose omission by device, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 624 | 25048721 |
US |
||
Labile blood pressure, Generalised tonic-clonic seizure, Accidental exposure to product, |
||||
TRANEXAMIC ACID, |
||||
| 625 | 25048740 |
US |
||
Accidental exposure to product, Rash, |
||||
METHIMAZOLE, |
||||
| 626 | 25048783 |
US |
34 | 1 |
Injury associated with device, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
ADALIMUMAB-BWWD, |
||||
| 627 | 25048847 |
US |
50 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, Injection site bruising, Liquid product physical issue, |
||||
ADALIMUMAB-BWWD, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 628 | 25048853 |
US |
75 | 2 |
Injection site pain, Needle issue, Accidental exposure to product, Incorrect dose administered, Device malfunction, Product dispensing issue, Exposure via skin contact, |
||||
ADALIMUMAB-BWWD, |
||||
| 629 | 25048881 |
US |
37 | 1 |
Dry eye, Accidental exposure to product, Wrong technique in product usage process, Incorrect dose administered, |
||||
ADALIMUMAB-BWWD, |
||||
| 630 | 25049169 |
US |
||
Status epilepticus, Accidental exposure to product, |
||||
TRANEXAMIC ACID, |
||||
| 631 | 25049349 |
US |
76 | |
Accidental exposure to product, Incorrect dose administered, Injection site pain, |
||||
BENRALIZUMAB, |
||||
| 632 | 25049573 |
US |
39 | 2 |
Device malfunction, Device difficult to use, Device leakage, Accidental exposure to product, |
||||
SECUKINUMAB, |
||||
| 633 | 25049601 |
US |
1 | |
Panic attack, Nervousness, Limb injury, Frustration tolerance decreased, Injection site haemorrhage, Injection site discomfort, Injection site pain, Incorrect dose administered, Exposure via skin contact, Accidental exposure to product, |
||||
ADALIMUMAB-BWWD, CETIRIZINE HYDROCHLORIDE, |
||||
| 634 | 25049603 |
US |
78 | 2 |
Injection site pain, Exposure via skin contact, Accidental exposure to product, Device issue, Incorrect dose administered, |
||||
ADALIMUMAB-BWWD, |
||||
| 635 | 25049665 |
US |
66 | 2 |
Injection site pain, Injection site haemorrhage, Exposure via skin contact, Accidental exposure to product, Device issue, |
||||
ADALIMUMAB-BWWD, ADALIMUMAB-BWWD, |
||||
| 636 | 25049670 |
US |
50 | 2 |
Accidental exposure to product, Paraesthesia, Wrong technique in device usage process, |
||||
ADALIMUMAB-BWWD, |
||||
| 637 | 25049976 |
US |
57 | 2 |
Injection site pain, Discomfort, Device leakage, Needle issue, Product substitution issue, Accidental exposure to product, |
||||
ADALIMUMAB-BWWD, |
||||
| 638 | 25049978 |
US |
60 | 2 |
Panic reaction, Accidental exposure to product, Exposure via skin contact, |
||||
ADALIMUMAB-BWWD, |
||||
| 639 | 25050025 |
US |
85 | 2 |
Injection site haemorrhage, Product dose omission issue, Accidental exposure to product, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 640 | 25050236 |
US |
73 | 2 |
Spinal operation, Brain fog, Accidental exposure to product, Drug dose omission by device, Wrong technique in product usage process, Limb injury, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 641 | 25050265 |
US |
51 | 2 |
Injection site erythema, Accidental exposure to product, Device malfunction, Exposure via skin contact, |
||||
ADALIMUMAB-BWWD, |
||||
| 642 | 25050275 |
US |
29 | 2 |
Fear of injection, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, Wrong technique in product usage process, |
||||
ADALIMUMAB-BWWD, |
||||
| 643 | 25050947 |
PT |
54 | 2 |
Accidental exposure to product, Exposure via mucosa, Angioedema, Cross sensitivity reaction, |
||||
SULFASALAZINE, |
||||
| 644 | 25051102 |
US |
66 | 2 |
Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, Muscle twitching, Device dislocation, |
||||
ADALIMUMAB-BWWD, ADALIMUMAB-BWWD, |
||||
| 645 | 25051103 |
US |
51 | 1 |
Skin burning sensation, Product leakage, Accidental exposure to product, Exposure via skin contact, Liquid product physical issue, |
||||
ADALIMUMAB-BWWD, |
||||
| 646 | 25051145 |
US |
2 | |
Exposure via skin contact, Device malfunction, Injection site haemorrhage, Accidental exposure to product, |
||||
ADALIMUMAB-BWWD, |
||||
| 647 | 25051156 |
US |
60 | 1 |
Agitation, Patient uncooperative, Accidental exposure to product, Exposure via skin contact, Device issue, |
||||
ADALIMUMAB-BWWD, |
||||
| 648 | 25051225 |
US |
1 | |
Injection site pain, Exposure via skin contact, Accidental exposure to product, Drug dose omission by device, Incorrect dose administered by device, Device leakage, Device malfunction, |
||||
ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, |
||||
| 649 | 25051548 |
US |
1 | |
Device malfunction, Device leakage, Exposure via skin contact, Accidental exposure to product, |
||||
SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, |
||||
| 650 | 25051599 |
CA |
38 | 2 |
Device leakage, Accidental exposure to product, |
||||
GOLIMUMAB, |
||||
| 651 | 25051664 |
US |
55 | 2 |
Dementia, Accidental exposure to product, Drug dose omission by device, |
||||
ETANERCEPT, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 652 | 25051733 |
US |
1 | |
Accidental exposure to product, Drug dose omission by device, Product administration interrupted, Device leakage, |
||||
SECUKINUMAB, LISINOPRIL, FLUOXETINE HYDROCHLORIDE, BENZOYL PEROXIDE, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE 4%, IBUPROFEN, IBUPROFEN AND DIPHENHYDRAMINE CITRATE, |
||||
| 653 | 25052077 |
US |
2 | |
Injection site pain, Wrong technique in product usage process, Incorrect dose administered, Accidental exposure to product, Exposure via skin contact, |
||||
ADALIMUMAB-BWWD, |
||||
| 654 | 25052079 |
US |
70 | 2 |
Injection site injury, Injection site bruising, Accidental exposure to product, Exposure via skin contact, Drug delivery system malfunction, Incorrect dose administered, Needle issue, |
||||
ADALIMUMAB-BWWD, ADALIMUMAB-BWWD, |
||||
| 655 | 25052080 |
US |
57 | 1 |
Injection site haemorrhage, Device issue, Incorrect dose administered, Exposure via skin contact, Accidental exposure to product, |
||||
ADALIMUMAB-BWWD, |
||||
| 656 | 25052081 |
US |
57 | 2 |
Injection site haemorrhage, Device leakage, Device issue, Exposure via skin contact, Accidental exposure to product, |
||||
ADALIMUMAB-BWWD, HYDROXYCHLOROQUINE, |
||||
| 657 | 25052091 |
US |
62 | 2 |
Injection site swelling, Injection site erythema, Injection site pruritus, Accidental exposure to product, Exposure via skin contact, Wrong technique in device usage process, |
||||
ADALIMUMAB-BWWD, |
||||
| 658 | 25052122 |
US |
45 | 1 |
Arthralgia, Accidental exposure to product, Exposure via skin contact, Device malfunction, |
||||
ADALIMUMAB-BWWD, |
||||
| 659 | 25052126 |
US |
52 | 2 |
Injection site bruising, Device leakage, Accidental exposure to product, Exposure via skin contact, Device difficult to use, Drug delivery system malfunction, |
||||
ADALIMUMAB-BWWD, ADALIMUMAB-BWWD, |
||||
| 660 | 25052670 |
US |
54 | 2 |
Accidental exposure to product, Device malfunction, Product dose omission issue, Off label use, |
||||
GUSELKUMAB, |
||||
| 661 | 25052756 |
US |
81 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 662 | 25052763 |
US |
2 | |
Ulcer, Dermatitis atopic, Accidental exposure to product, Exposure via skin contact, Device operational issue, |
||||
DUPILUMAB, DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), LINACLOTIDE, |
||||
| 663 | 25052773 |
US |
71 | 2 |
Injection site bruising, Injection site swelling, Injection site pain, Rash, Exposure via skin contact, Device mechanical issue, Accidental exposure to product, Device issue, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 664 | 25052778 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 665 | 25052780 |
US |
72 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 666 | 25052790 |
US |
22 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 667 | 25052798 |
US |
64 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 668 | 25052811 |
US |
60 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 669 | 25052829 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 670 | 25052836 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 671 | 25052852 |
US |
63 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 672 | 25052865 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 673 | 25052881 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 674 | 25052897 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 675 | 25052901 |
US |
22 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 676 | 25052961 |
US |
59 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, |
||||
| 677 | 25053058 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 678 | 25053073 |
US |
13 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 679 | 25053076 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 680 | 25053079 |
US |
42 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 681 | 25053090 |
US |
79 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 682 | 25053095 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 683 | 25053106 |
US |
69 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 684 | 25053112 |
US |
6 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 685 | 25053114 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 686 | 25053143 |
US |
25 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 687 | 25053179 |
US |
43 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 688 | 25053201 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 689 | 25053281 |
US |
11 | 2 |
Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 690 | 25053314 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 691 | 25053321 |
US |
13 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 692 | 25053358 |
US |
28 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 693 | 25053370 |
US |
58 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 694 | 25053395 |
US |
89 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 695 | 25053447 |
US |
81 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 696 | 25053455 |
US |
45 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 697 | 25053476 |
US |
92 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 698 | 25053480 |
US |
20 | 1 |
Injection site pain, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 699 | 25053485 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 700 | 25053505 |
US |
71 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28